Xenon Pharmaceuticals Inc.
NASDAQ:XENEBiotechnology
-$0.29 today
- Market cap
- $3.71B
- Beta
- 0.63
- P/E (TTM)
- -12.1
- EPS (TTM)
- -$4.39
Volume 1.30M
Average 1.16M
XENE EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Xenon Pharmaceuticals Inc.NASDAQ: XENE
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$108.03M, compared with -$89.58M a year earlier. Trailing-twelve-month EBITDA was -$434.65M.
Context
- EBITDA amounted to 4564.7% of revenue in FY2025.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of -$362.84M (-6.0%) for the fiscal year ending Dec 2026, a step up from the -45.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$108.03M+2.5% QoQ
- Last fiscal yearDec 2025
- -$342.35M-45.2% YoY
- LTMSep 2026
- -$434.65M-30.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -20.6% | +99.7% | +120.3 pp |
| 1 year | -45.2% | -6.0% | +39.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (342.35M) USD
- Year-over-year change
- -45.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (342.35M) | -45.2% |
| FY2024 | 2024-12-31 | (235.86M) | -12.0% |
| FY2023 | 2023-12-31 | (210.51M) | -64.8% |
| FY2022 | 2022-12-31 | (127.74M) | -63.6% |
| FY2021 | 2021-12-31 | (78.09M) | — |
EBITDA vs competitors
How XENE compares with its peers on the latest reported figures
- XENE's LTM Sep 2026 EBITDA of -$434.65M is the 10th highest of the 11 companies compared; the peer median is -$78.51M.
- Its year-over-year change of -30.9% is the 9th highest of 11, against a peer median of +10.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $990.56M | +284.7% | -43.7% | 21.0% | |
| LTM Sep 2026 | $949.9M | +39.8% | +41.2% | 25.7% | |
| LTM Sep 2026 | $140.29M | +5.0% | — | 11.7% | |
| LTM Jun 2026 | -$15.87M | -109.6% | -34.8% | 1.9% | |
| LTM Dec 2025 | -$38.87M | +24.6% | — | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$118.15M | -28.2% | — | 590.7% |
| LTM Jun 2026 | -$176.13M | +22.9% | — | 22.7% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$217.64M | +15.4% | — | — |
| LTM Sep 2026 | -$359.29M | -31.7% | — | — | |
| LTM Sep 2026 | -$434.65M | -30.9% | — | — | |
| LTM Jun 2026 | -$498.21M | -6.5% | — | 13823.7% | |
| Peer median (excluding XENE) | -$78.51M | +10.2% | -34.8% | 22.7% | |
Competitors are the stored peer set for XENE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.44M | 9.43M | 0 | 0 | 7.5M |
| Cost of Revenue | 0 | 0 | 167.51M | 2.56M | 2.54M |
| Gross Profit | 18.44M | 9.43M | (167.51M) | (2.56M) | 4.96M |
| Gross Margin | 100.0% | 100.0% | — | — | 66.1% |
| Research & Development | 75.46M | 105.77M | 167.51M | 210.39M | 300.94M |
| Selling, General & Admin | 21.97M | 32.81M | 46.54M | 68.9M | 79.63M |
| Operating Expenses | 97.43M | 138.58M | 46.54M | 276.74M | 378.03M |
| Depreciation & Amortization | 906K | 1.41M | 3.54M | 2.56M | 2.54M |
| EBITDA | (78.09M) | (127.74M) | (210.51M) | (235.86M) | (342.35M) |
| EBITDA Margin | -423.5% | -1354.0% | — | — | -4564.7% |
| Operating Income | (78.99M) | (129.14M) | (214.05M) | (279.3M) | (373.07M) |
| Operating Margin | -428.4% | -1368.9% | — | — | -4974.3% |
| Interest Income | 466K | 8.71M | 27.62M | 41.94M | 26.83M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 105K | 3.89M | 31.37M | 40.88M | 28.18M |
| Income Before Tax | (78.89M) | (125.26M) | (182.69M) | (238.42M) | (344.89M) |
| Pre-Tax Margin | -427.9% | -1327.7% | — | — | -4598.6% |
| Income Tax Expense | (6K) | 118K | (292K) | (4.09M) | 1.02M |
| Net Income | (78.88M) | (125.37M) | (182.39M) | (234.33M) | (345.91M) |
| Net Margin | -427.8% | -1328.9% | — | — | -4612.1% |
| EPS (Basic) | (1.77) | (2.06) | (2.73) | (3.01) | (4.36) |
| EPS (Diluted) | (1.77) | (2.06) | (2.73) | (3.01) | (4.36) |
| Weighted Avg Shares | 43.63M | 60.54M | 66.89M | 77.89M | 79.25M |
| Weighted Avg Shares (Diluted) | 43.63M | 60.54M | 66.89M | 77.89M | 79.25M |
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
Intrinsic Alpha fair value
Locked
Current Price
$37.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.